Amgen, Inc. vs Enphase Energy Inc — how do they compare? Amgen, Inc. trades at $414.13 (market cap $224.14B), while Enphase Energy Inc trades at $42.74 (market cap $5.59B). The key difference: Amgen, Inc. is far larger — about 40.1× Enphase Energy Inc's market cap, and Amgen, Inc. pays a 2.43% dividend while Enphase Energy Inc pays none. Which is the better fit depends on your goals.
| AMGN | ENPH | |
|---|---|---|
Market Cap | $224.14B | $5.59B |
Sector | Health | Technology |
52-Week High | $417.20 | $72.33 |
52-Week Low | $271.18 | $26.12 |
Enterprise Value | $267.45B | $5.23B |
Dividend Yield | 2.43% | — |
Trailing returns across standard periods
Latest headlines on both assets
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.
Read more on ENPH →